Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
11.81
+0.48 (4.24%)
Aug 13, 2025, 4:00 PM - Market closed
Cartesian Therapeutics Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for Cartesian Therapeutics stock ranges from a low of $38 to a high of $42. The average analyst price target of $40 forecasts a 238.70% increase in the stock price over the next year.
Price Target: $40.00 (+238.70%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jul 9, 2025.
Analyst Ratings
The average analyst rating for Cartesian Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 4 | 3 |
| Buy | 1 | 1 | 0 | 0 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 7 | 7 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Initiates $38 | Buy | Initiates | $38 | +221.76% | Jul 9, 2025 |
| Needham | Needham | Strong Buy Maintains $41 → $40 | Strong Buy | Maintains | $41 → $40 | +238.70% | May 8, 2025 |
| Needham | Needham | Strong Buy Reiterates $41 | Strong Buy | Reiterates | $41 | +247.16% | Apr 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +238.70% | Apr 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $45 → $40 | Strong Buy | Maintains | $45 → $40 | +238.70% | Mar 14, 2025 |
Financial Forecast
Revenue This Year
3.77M
from 38.91M
Decreased by -90.30%
Revenue Next Year
905.25K
from 3.77M
Decreased by -76.01%
EPS This Year
-3.31
from -4.49
EPS Next Year
-3.81
from -3.31
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 21.0M | 4.6M | 4.6M | ||
| Avg | 3.8M | 905,250 | 1.1M | ||
| Low | 1.1M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -46.0% | 22.4% | 410.4% | ||
| Avg | -90.3% | -76.0% | 23.9% | ||
| Low | -97.2% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.78 | -2.26 | -2.08 |
| Avg | -3.31 | -3.81 | -4.06 |
| Low | -3.84 | -4.41 | -5.79 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.